Beta-Blocker Therapy After Heart Attack: Heart Function Matters
Hear’s a breakdown of the facts provided, focusing on the key takeaways and the speaker:
Key Takeaways from Dr.Kramer’s Statement:
Beta-Blockers After MI: Patients who have a normal ejection fraction (EF) after a myocardial infarction (MI – heart attack) likely do not need long-term treatment with beta-blockers.
EF < 50%: Patients with an EF less than 50% do benefit from beta-blockers, primarily in preventing recurrent MIs.
data Support: This conclusion is based on a meta-analysis and data from trials like BETAMI-DANBLOCK and REBOOT-CNIC. BETAMI-DANBLOCK had a larger patient population with EF between 40-49% than REBOOT-CNIC.
Guideline Updates: Dr. Kramer believes current guidelines should be updated to reflect these findings and anticipates they will be.
Speaker Information:
Name: Christopher M. Kramer, MD
Title: George A. Beller/Lantheus Medical Imaging Distinguished Professor of Cardiovascular Medicine; Chief, Cardiovascular Division
Institution: UVA Health
Professional Role: President, American College of Cardiology
Disclosures: Reports no relevant financial disclosures.
Source Information:
Presentation: the information was presented at the European Society of Cardiology Congress, august 29-September 1, 2025, in Madrid.
Citation: Ibanez B, et al. Hot line 3.
Disclosures (of presenters): Ibáñez, Prescott and Rosselló report no relevant financial disclosures. Atar reports receiving speaker fees from multiple pharmaceutical companies (Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, GlaxoSmithKline, Novartis, Novo nordisk, Pfizer, Pharmacosmos, philips, Roche Diagnostics, Sanofi, Takeda and Vifor).in essence, Dr.kramer is advocating for a more targeted approach to beta-blocker use after MI,based on a patient’s ejection fraction.